What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce and furnish Amgen's unaudited financial results for the third quarter and the first nine months of 2024, as detailed in a press release issued on October 30, 2024. It provides investors with key financial performance indicators and insights into the company's operations during the reported periods.

What are non-GAAP financial measures, and why does Amgen use them?

Non-GAAP financial measures are financial metrics that exclude certain items from the corresponding GAAP (Generally Accepted Accounting Principles) measures. Amgen uses them, such as non-GAAP earnings per share and operating income, to provide a more meaningful view of its ongoing business performance. By excluding items like acquisition-related costs, restructuring charges, and certain investment gains/losses, Amgen aims to facilitate better comparisons of operational results across different periods and with its peers.

What specific types of expenses does Amgen exclude when calculating its non-GAAP financial measures?

Amgen typically excludes acquisition-related expenses (such as amortization of acquired intangibles), costs associated with restructuring and cost savings initiatives (including facility charges and severance), and other items considered outside the ordinary course of business. These 'other items' can include gains or losses on equity investments and specific legal settlements or debt issuance costs. The company provides detailed reconciliations in its press release.

Is the information in the press release considered 'filed' with the SEC?

No, the information contained in the press release furnished under Item 2.02 of this Current Report is generally not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into any future SEC filings by Amgen unless specifically stated. Investors should treat this information as supplementary.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) has filed an 8-K report on October 30, 2024, to announce its unaudited third quarter and year-to-date financial results for 2024. The report primarily furnishes a press release detailing these results, which include both GAAP and non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP figures such as adjusted earnings per share, operating income, and free cash flow to provide a more transparent view of ongoing business performance and facilitate comparisons across periods, excluding items like acquisition-related expenses, restructuring costs, and certain investment gains/losses or debt-related charges. The press release itself, furnished as an exhibit, contains the detailed financial performance for the three and nine months ended September 30, 2024. The company emphasizes that these non-GAAP measures are supplementary and not a replacement for GAAP reporting. The rationale behind excluding certain items is to present a clearer picture of operational profitability by treating internally developed assets comparably to acquired ones and by removing volatile or non-recurring charges. Investors are encouraged to review the full press release for specific figures and the reconciliations between GAAP and non-GAAP metrics.

Key Highlights

1Amgen Inc. reported its unaudited third quarter and year-to-date 2024 financial results on October 30, 2024.
2The 8-K filing includes a press release detailing the company's financial performance for the periods ending September 30, 2024.
3Amgen presented both GAAP and non-GAAP financial measures, including non-GAAP earnings per share, operating income, and operating margin.
4The company also reported Free Cash Flow (FCF) as a key liquidity metric.
5Non-GAAP measures exclude acquisition-related expenses, restructuring and cost savings initiatives, and certain other income/expense items deemed outside the ordinary course of business.
6Amgen states its use of non-GAAP measures is to enhance investor understanding of ongoing business performance and facilitate period-over-period comparisons.
7The press release, furnished as Exhibit 99.1, contains the full details and reconciliations of GAAP to non-GAAP financial information.

AMGEN INC 8-K Report, Financial Results (Oct 30, 2024)

Summary

Key Highlights

Frequently Asked Questions